BioRestorative Therapies Files S-1/A Amendment

TL;DR

<b>BioRestorative Therapies, Inc. has filed an S-1/A amendment, indicating potential future securities offerings.</b>

AI Summary

BioRestorative Therapies, Inc. (BRTX) filed a Amended IPO Registration (S-1/A) with the SEC on April 12, 2024. BioRestorative Therapies, Inc. filed an S-1/A registration statement amendment on April 12, 2024. The filing is for a registration statement under the Securities Act of 1933. The company's principal executive offices are located at 40 Marcus Drive, Suite One, Melville, New York 11747. Lance Alstodt is listed as the President and Chief Executive Officer. The filing indicates the securities may be offered on a delayed or continuous basis pursuant to Rule 415.

Why It Matters

For investors and stakeholders tracking BioRestorative Therapies, Inc., this filing contains several important signals. This S-1/A filing is a procedural step for BioRestorative Therapies to potentially offer securities in the future, which could impact its capital structure and shareholder base. The registration statement allows for delayed or continuous offerings, suggesting a strategy for ongoing capital raising or liquidity events.

Risk Assessment

Risk Level: low — BioRestorative Therapies, Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, which is a standard regulatory process and does not inherently indicate significant new risks or changes in the company's financial or operational status.

Analyst Insight

Monitor future filings for details on any actual securities offerings and their terms.

Key Numbers

• 2024-04-12 — Filing Date (Date of S-1/A filing)
• 1933 — Securities Act (Act under which registration is filed)
• 415 — Rule (Rule for delayed/continuous offerings)

Key Players & Entities

• BioRestorative Therapies, Inc. (company) — Registrant
• Securities and Exchange Commission (regulator) — Filing body
• Lance Alstodt (person) — President and Chief Executive Officer
• Fred Skolnik (person) — Agent for service
• Certilman Balin Adler & Hyman, LLP (company) — Legal counsel
• 333-278488 (registration_number) — Registration number

FAQ

Industry Context

BioRestorative Therapies operates in the health and allied services sector, focusing on therapies that may involve regenerative medicine or similar advanced treatments.

Regulatory Implications

The filing is made under the Securities Act of 1933, requiring adherence to SEC regulations for public offerings of securities.

What Investors Should Do

1. Review the full S-1/A filing for specific details on the proposed securities and offering terms.
2. Track future SEC filings from BioRestorative Therapies for updates on capital raising activities.
3. Analyze the company's business strategy and financial health in conjunction with any announced offerings.

Key Dates

• 2024-04-12: Filing of S-1/A Amendment — Indicates potential future securities offerings and regulatory compliance.

Glossary

S-1/A

An amendment to a registration statement filed with the SEC. (Indicates updates or changes to a previously filed registration statement.)

Securities Act of 1933

A federal law regulating the initial offering and sale of securities. (Governs the requirements for registering securities with the SEC.)

Rule 415

Allows for the delayed or continuous offering and sale of securities. (Provides flexibility for companies to raise capital over time.)

Year-Over-Year Comparison

This is an amendment to a previous filing, suggesting updates or additions to the initial registration statement.

Filing Documents

• s_1a1.htm (S-1/A) — 94KB
• 0001021771-24-000099.txt (&nbsp;) — 95KB

Exhibits

Item 16. Exhibits. Exhibit Number Exhibit Description 3.1 Amended and Restated Articles of Incorporation, incorporated by reference to the registrant's Current Report on Form 8-K for an event dated December 29, 2022, wherein such document is identified as Exhibit 3.3 3.2 Certificate of Designations of Series B Preferred Stock, incorporated by reference to the registrant's Current Report on Form 8-K for an event dated December 29, 2022, wherein such document is identified as Exhibit 3.4 3.3 Bylaws, incorporated by reference to the registrant's Current Report on Form 8-K for an event dated December 29, 2022, wherein such document is identified as Exhibit 3.5 5.1 Opinion of Certilman Balin Adler & Hyman, LLP* 10.1 License Agreement, dated as of January 27, 2012, between Regenerative Sciences, LLC and BioRestorative Therapies, Inc. ("License Agreement"), incorporated by reference to the registrant's Annual Report on Form 10-K for the year ended December 31, 2011, wherein such document is identified as Exhibit 10.44 10.2 Amendment to License Agreement, dated March 21, 2012, incorporated by reference to the registrant's Annual Report on Form 10-K for the year ended December 31, 2011, wherein such document is identified as Exhibit 10.45 10.3 Amendment to License Agreement, dated November 30, 2015, incorporated by reference to the registrant's Annual Report on Form 10-K for the year ended December 31, 2015, wherein such document is identified as Exhibit 10.20 10.4 Letter agreement, dated November 21, 2022, by and among BioRestorative Therapies, Inc., Regenerative Sciences, LLC and Regenexx, LLC with regard to License Agreement, incorporated by reference to the registrant's Annual Report on Form 10-K for the year ended December 31, 2022, wherein such document is identified as Exhibit 10.4 10.5 Lease, dated as of August 25, 2014, between BioRestorative Therapies, Inc. and 50 Republic Road, LLC, incorporated by reference to the registrant'

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Amendment No. 1 to registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Melville, New York, on April 12, 2024. BIORESTORATIVE THERAPIES, INC. By: /s/ Lance Alstodt Lance Alstodt President, Chief Executive Officer and Chairman of the Board Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated. Signature Title Date /s/Lance Alstodt President, Chief Executive Officer and Chairman of the Board (Principal Executive Officer) April 12, 2024 Lance Alstodt * Vice President, Research and Development, Secretary and Director April 12, 2024 Francisco Silva * Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) April 12, 2024 Robert E. Kristal * Director April 12, 2024 Nickolay Kukekov * Director April 12, 2024 Patrick F. Williams * Director April 12, 2024 David Rosa *By: /s/ Lance Alstodt Lance Alstodt Attorney-In-Fact

View Full Filing

View this S-1/A filing on SEC EDGAR